OS Therapies (NYSE:OSTX) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of OS Therapies (NYSE:OSTX) in a research note released on Thursday,Benzinga reports. The brokerage currently has a $20.00 price objective on the stock.

Separately, Maxim Group increased their target price on shares of OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, January 16th.

OS Therapies Price Performance

OS Therapies stock opened at $1.89 on Thursday. OS Therapies has a one year low of $1.58 and a one year high of $7.00. The company’s fifty day moving average price is $3.31 and its two-hundred day moving average price is $3.14.

Insiders Place Their Bets

In other OS Therapies news, major shareholder Shalom Auerbach sold 16,720 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total transaction of $112,692.80. Following the completion of the sale, the insider now directly owns 2,531,211 shares in the company, valued at $17,060,362.14. This represents a 0.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Institutional Investors Weigh In On OS Therapies

A hedge fund recently raised its stake in OS Therapies stock. CM Management LLC lifted its stake in OS Therapies Inc (NYSE:OSTX) by 120.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 110,044 shares of the company’s stock after buying an additional 60,044 shares during the period. CM Management LLC owned about 0.51% of OS Therapies worth $471,000 at the end of the most recent reporting period.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.